Geode Capital Management LLC Purchases 272,813 Shares of Inhibikase Therapeutics, Inc. (NYSE:IKT)

Geode Capital Management LLC increased its position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT - Free Report) by 544.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 322,878 shares of the company's stock after acquiring an additional 272,813 shares during the period. Geode Capital Management LLC owned approximately 0.47% of Inhibikase Therapeutics worth $1,049,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Blair William & Co. IL increased its holdings in shares of Inhibikase Therapeutics by 7.0% in the fourth quarter. Blair William & Co. IL now owns 134,953 shares of the company's stock worth $439,000 after purchasing an additional 8,833 shares during the period. Institutional investors own 3.81% of the company's stock.

Inhibikase Therapeutics Stock Down 7.2 %

Shares of IKT stock traded down $0.15 during trading on Tuesday, hitting $1.94. The company had a trading volume of 131,358 shares, compared to its average volume of 231,766. The stock's 50-day moving average is $2.12 and its two-hundred day moving average is $2.52. The stock has a market capitalization of $144.22 million, a price-to-earnings ratio of -0.73 and a beta of 1.01. Inhibikase Therapeutics, Inc. has a 52 week low of $1.12 and a 52 week high of $4.20.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a "neutral" rating on shares of Inhibikase Therapeutics in a research note on Friday, March 28th.

Inhibikase Therapeutics Profile

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.